Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

@inproceedings{Byron2012SensitivityTT,
  title={Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status},
  author={Sara A. Byron and David C. Loch and Candice L. Wellens and Andreas Wortmann and Jiayi Wu and John J. Wang and Kenichi Nomoto and Pamela M. Pollock},
  booktitle={Molecular Cancer},
  year={2012}
}
Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies. Despite these advances, resistance remains an issue, as illustrated recently by the clinical experience with vemurafenib. Such acquired resistance appears to be the result of parallel pathway activation, such as PI3K, to overcome single-agent inhibition. In this report, we describe the cytotoxicity and anti-tumour… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

CTC biomarker assessment to aid dosing schedule of E6201, a potential MEK1 inhibitor for treatment of BRAF-mutated melanoma [abstract

A Eisen, C Akerele, +5 authors J Wang
Ann Oncol 2010, • 2010
View 7 Excerpts
Highly Influenced

BRAF mutation predicts sensitivity to MEK inhibition

Nature • 2006
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…